Amgen Inc.

Michael Brian Bass

Murray O Robinson

Steven Roy Coats

John Kevin Sullivan

Lars Eyde Theill

Daguang Wang

Shuqian Jing

Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

DKR polypeptides

The present invention provides Fibroblast Growth Factor-Like (FGF-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGF-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGF-L polypeptides.

Fibroblast growth factor-like molecules and uses thereof

Disclosed are nucleic acid molecules encoding cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Antibodies to cyclin E2 protein

Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Growing community of inventors

Thousand Oaks, CA, United States of America

Michael Brian Bass